Technology ❯ Biotechnology

Drug Development

Clinical Trials GLP-1 Agonists Antiviral Drugs Antivenom Research Peptide Therapies Immunotherapies AI in Healthcare Natural Products NaV1.8 Inhibitors Non-Hormonal Contraceptives Targeted Protein Degradation Neuroscience Research and Development Longevity Research Conjugation Technologies Immunotherapy mRNA Technology MorphoSys Innovations Targeted Therapies Oligonucleotide Drugs Combination Therapy Cancer Drugs Innovative Therapies RNA Therapeutics High-Throughput Screening Therapeutic Innovations Personalized Medicine Oral Formulations Computational Chemistry Global Supply Chains Machine Learning Preclinical Research Therapeutic Techniques Clinical Applications Computational Methods Press Releases Peptide Therapy Biosimilars Antibiotic Design Antibiotic Alternatives Synthetic Biology Royalty Models Formulation Technologies Antivenom Production Laboratory Infrastructure

Moderna’s Phase 3 Melanoma Win Reprices the Company

Late‑stage success for the personalized vaccine reduces clinical uncertainty for intismeran and has driven a sharp re‑rating of Moderna’s stock while key commercial questions remain.

Novo Nordisk Licenses Vivtex Platform in $2.1 Billion Push for Oral Obesity and Diabetes Drugs

New Single-Particle Assay Finds Disordered Lipid Nanoparticles Release RNA More Effectively

Bristol Myers, Janux Strike Exclusive Deal on Tumor-Activated T-Cell Engager

Johnson & Johnson to Buy Halda Therapeutics for $3.05 Billion to Bolster Oncology Pipeline

Merck to Buy Cidara for $9.2 Billion to Secure Long-Acting Flu Drug

Tubulis Raises €308 Million Series C to Accelerate Lead Cancer ADC

CUNY Study Unveils Sugar-Targeting Compounds With Broad Antiviral Activity

Mix-and-Go Cubosome Method Achieves Over 98% mRNA Encapsulation and Advances Toward Clinical Scale-Up

Astrocyte-Derived Peptide Achieves Nausea-Free Weight Loss in Animal Models

Researchers Transform Ancient Tomb Fungus Into Potent Antileukemia Compound